39 results
D
NLSP
NLS Pharmaceutics Ltd
3 Apr 24
$1.75 mm in equity / options / securities to be acquired, sold $1.75 mm, 2 investors
4:01pm
require offering materials under this undertaking or otherwise and can require offering materials only to the
extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.
6-K
EX-10.1
NLSP
NLS Pharmaceutics Ltd
21 Mar 24
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
5:14pm
) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and the Prospectus … , contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating to the manufacture
6-K
EX-99.2
NLSP
NLS Pharmaceutics Ltd
6 Dec 23
Unaudited Interim Condensed Financial Statements
4:44pm
as well as expenses related to lab supplies, materials and facility costs.
Clinical trial costs are a major component of research and development expenses
6-K
EX-99.1
s24l3 397no
16 Nov 23
Report of Foreign Private Issuer
4:05pm
6-K
EX-99.1
r8xw5r65
25 Oct 23
Report of Foreign Private Issuer
9:02am
6-K
EX-99.1
bm1dbleae
20 Jul 23
Report of Foreign Private Issuer
4:06pm
6-K
EX-99.3
n4ta8s1dax0bq5eu
3 Jul 23
NLS Pharmaceutics Releases the Results from its Annual General Meeting
1:22pm
D
zuzceg9
21 Dec 22
$30.00 mm in equity / options / securities to be acquired, sold $10.00 mm, 4 investors
4:01pm
6-K
EX-99.3
kmkr f77oa
8 Dec 22
Report of Foreign Private Issuer
4:30pm
D
9wu3sm9
14 Oct 22
$4.00 mm in equity / options, sold $4.00 mm, 5 investors
6:07am
6-K
EX-99.2
001dp
11 Oct 22
Unaudited Interim Condensed Financial Statements
5:20pm
6-K
EX-99.2
sh43joxdtabk3f4xiq
3 Oct 22
Report of Foreign Private Issuer
8:51am
6-K
EX-10.2
cobx 8ycjq
14 Apr 22
NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:58pm
6-K
EX-10.1
gktblb1x9gvz
14 Apr 22
NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:58pm
6-K
EX-1.1
b8p tcgddl
4 Mar 22
Report of Foreign Private Issuer
4:02pm
6-K
EX-99.2
k1ut0e oz8z
28 Sep 21
Unaudited Interim Condensed Financial Statements
4:02pm